โก Quick Summary
This review article explores the evolving role of biomarkers in the management of localized high-risk prostate cancer (PC), highlighting the limitations of traditional clinicopathological parameters. The integration of genomic profiling and advanced technologies is paving the way for more precise and personalized treatment strategies.
๐ Key Details
- ๐ Focus: Localized high-risk prostate cancer
- ๐ฌ Techniques: Tumor genomic profiling, radiomic features, next-generation sequencing
- ๐งฌ Biomarkers: Prostate-specific antigen tests and genomic classifiers
- โ๏ธ Clinical Application: Decision-making in treatment strategies
๐ Key Takeaways
- ๐ High-risk PC accounts for 50-75% of 10-year relapse rates post-treatment.
- ๐ Traditional parameters are often inadequate for patient stratification.
- ๐ก Genomic profiling enhances diagnostic accuracy and risk prediction.
- ๐ค AI and automated platforms are being integrated into clinical practice.
- ๐ Emerging biomarkers show improved sensitivity and specificity for significant PC detection.
- ๐งฉ Personalized medicine is becoming a reality through tailored therapeutic decisions.
- ๐ Future research is essential for further validation and application of these biomarkers.
๐ Background
Prostate cancer remains a significant health concern, particularly in its high-risk localized form. Traditional methods of stratifying patients based on clinicopathological parameters have proven insufficient, leading to a pressing need for more accurate diagnostic tools. The advent of biomarkers offers a promising avenue for enhancing patient management and treatment outcomes.
๐๏ธ Study
This narrative review synthesizes current knowledge on both established and emerging biomarkers in localized high-risk prostate cancer. The authors delve into the molecular mechanisms underlying prostate carcinogenesis and assess the impact of advanced technologies such as next-generation sequencing and artificial intelligence in refining risk assessment and treatment strategies.
๐ Results
The findings underscore the potential of novel biomarkers to significantly improve the sensitivity and specificity of prostate cancer detection. Additionally, commercially available genomic classifiers have shown promise in enhancing the prediction of disease recurrence, progression, and metastasis when combined with traditional clinical variables.
๐ Impact and Implications
The integration of advanced biomarker testing into clinical practice could revolutionize the management of localized high-risk prostate cancer. By enabling more accurate risk stratification and personalized treatment plans, these advancements hold the potential to improve patient outcomes and reduce relapse rates significantly. The ongoing evolution in this field is crucial for the future of precision oncology.
๐ฎ Conclusion
This review highlights the transformative potential of biomarkers in the landscape of localized high-risk prostate cancer management. As we continue to refine our understanding and application of these tools, the future of prostate cancer treatment looks increasingly promising. Continued research and clinical validation are essential to fully realize the benefits of these advancements in patient care.
๐ฌ Your comments
What are your thoughts on the evolving role of biomarkers in prostate cancer management? We would love to hear your insights! ๐ฌ Join the conversation in the comments below or connect with us on social media:
The Evolving Landscape of Novel and Old Biomarkers in Localized High-Risk Prostate Cancer: State of the Art, Clinical Utility, and Limitations Toward Precision Oncology.
Abstract
High-risk prostate cancer (PC) accounts for 50-75% of 10-year relapse after primary treatment. Routine clinicopathological parameters for PC patient stratification have proven insufficient to inform clinical decisions in this setting. Tumor genomic profiling allowed overcoming the limits of diagnostic accuracy in the field of PC, integrated with radiomic features, automated platforms, evaluation of patient-related factors (age, performance status, comorbidity) and tumor-related factors (risk class, volume, T stage). In this scenario, the use of biomarkers to guide decision-making in localized, high-risk PC is evolving actively and rapidly. Additional tests for prostate-specific antigen have demonstrated superior sensitivity and specificity for detecting clinically significant PC, as well as commercially available genomic classifiers improving the risk prediction of disease recurrence/progression/metastasis, in combination with common clinical variables. This narrative review aimed to summarize the state of the art on the utility and evolution of old and emerging biomarkers in the diagnosis and prognosis of localized, high-risk PC, and the potential for their application in clinical practice. We focused on the theoretical molecular foundation of prostate carcinogenesis and explored the impact of genomic profiling, next-generation sequencing, and artificial intelligence in the extrapolation of customized features able to predict disease aggressiveness and possibly drive personalized therapeutic decisions.
Author: [‘Bardoscia L’, ‘Sardaro A’, ‘Quattrocchi M’, ‘Cocuzza P’, ‘Ciurlia E’, ‘Furfaro I’, ‘Gilio MA’, ‘Mignogna M’, ‘Detti B’, ‘Ingrosso G’]
Journal: J Pers Med
Citation: Bardoscia L, et al. The Evolving Landscape of Novel and Old Biomarkers in Localized High-Risk Prostate Cancer: State of the Art, Clinical Utility, and Limitations Toward Precision Oncology. The Evolving Landscape of Novel and Old Biomarkers in Localized High-Risk Prostate Cancer: State of the Art, Clinical Utility, and Limitations Toward Precision Oncology. 2025; 15:(unknown pages). doi: 10.3390/jpm15080367